Tatva Chintan Pharma Chem (TATVA) Fundamentals 2026 — P/E 92.6x, Revenue Analysis | SniperIQ
Tatva Chintan Pharma Chem (TATVA) is a India-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ₹3,895 Crore, trading at ₹1665.60 on the BSE. This SniperIQ fundamentals page covers Tatva Chintan Pharma Chem's valuation (P/E 92.6x, P/B 5.0x), profitability (net margin 8.3%), revenue (₹506 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tatva Chintan Pharma Chem's market cap?
Tatva Chintan Pharma Chem (TATVA) has a market capitalization of approximately ₹3,895 Crore, trading at ₹1665.60 on the BSE. Market cap moves with the live share price.
What is Tatva Chintan Pharma Chem's P/E ratio?
Tatva Chintan Pharma Chem's trailing twelve-month P/E ratio is 92.6x, with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem runs a net profit margin of 8.3%, a gross margin of 45.2%, and an operating margin of 11.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tatva Chintan Pharma Chem generate?
Tatva Chintan Pharma Chem reported revenue of ₹506 Crore for fiscal year 2026, with net income of ₹42 Crore and earnings per share (EPS) of 17.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tatva Chintan Pharma Chem pay a dividend?
Tatva Chintan Pharma Chem offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tatva Chintan Pharma Chem financially healthy?
Tatva Chintan Pharma Chem carries a debt-to-equity ratio of 0.15x and a current ratio of 1.64x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tatva Chintan Pharma Chem a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tatva Chintan Pharma Chem (TATVA) the key facts are: market cap ₹3,895 Crore, P/E 92.6x, revenue ₹506 Crore, 52-week range 977.85-1786.7. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Tatva Chintan Pharma Chem's full fundamentals live
Get Tatva Chintan Pharma Chem's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.